Key Segments:
By Indication
-
Atopic Dermatitis
-
Asthma
-
Chronic Rhinosinusitis with Nasal Polyps
-
Eosinophilic Esophagitis
-
Chronic Obstructive Pulmonary Disease
-
Prurigo Nodularis
-
Bullous Pemphigoid
By Distribution Channel
-
Hospital Pharmacies
-
Retail Pharmacies
-
Specialty/Online Pharmacies
By Age Group
-
Adults
-
Pediatric
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Poland
-
Russia
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
The therapy is jointly developed and commercialized by Regeneron Pharmaceuticals and Sanofi, with distribution supported by major specialty and retail pharmacy networks including CVS Health, Walgreens Boots Alliance, and OptumRx, among others.
Continued pipeline expansion into additional type 2 inflammatory and autoimmune indications and the continued integration of artificial intelligence in clinical trial design represent the two most significant opportunities shaping the market's next phase of growth.
Growth is primarily driven by continued indication expansion, combined with rising global prevalence of type 2 inflammatory diseases.
By Indication, Atopic Dermatitis dominated the market with a 38.60% share in 2025, reflecting its status as the original and most extensively studied approved use.
North America held a dominant share of 76.20% in 2025, driven by advanced healthcare infrastructure and favorable reimbursement frameworks.
